AstraZeneca Plc is to co-develop a second antibody-drug conjugate (ADC) with Daiichi Sankyo Co Ltd of Japan, this time with the goal of treating multiple cancers with a single drug. The compound, DS-1062, is in early clinical development for non-small cell lung cancer and breast cancer, both of which overexpress the cell-surface glycoprotein Trop2. This protein is overexpressed on a wide variety of tumours.
